HÃ¥kan L Olsson

List of Publications by Year
in descending order

297 papers	22,620 citations	13865 67 h-index	11308 136 g-index
317 all docs	317 docs citations	317 times ranked	25262 citing authors

#	Article	IF	Citations
1	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
4	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Journal of the National Cancer Institute, 2022, 114, 540-552.	6.3	7
5	A Genome-Wide Gene-Based Geneâ€“Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219.	1.7	6
6	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
7	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
8	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
9	Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2021, 113, 318-328.	6.3	19
10	Common Susceptibility Loci for Male Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 453-461.	6.3	12
11	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
12	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
13	Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients. Scientific Reports, 2021, 11, 5307.	3.3	14
14	Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Translational Oncology, 2021, 14, 101029.	3.7	29
15	Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families. BMC Public Health, 2021, 21, 692.	2.9	4
16	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.7	6
17	The human melanoma proteome atlasâ€"Defining the molecular pathology. Clinical and Translational Medicine, 2021, 11, e473.	4.0	14
18	The Human Melanoma Proteome Atlasâ€"Complementing the melanoma transcriptome. Clinical and Translational Medicine, 2021, 11, e451.	4.0	20

#	Article	IF	Citations
19	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
20	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	1.3	34
21	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
22	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
23	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
24	Genetic testing in women with early-onset breast cancer: a Traceback pilot study. Breast Cancer Research and Treatment, 2021, 190, 307-315.	2.5	1
25	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
26	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
27	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. Journal of Medical Genetics, 2020, 57, 316-321.	3.2	33
28	Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228â€‰951 Women of European Descent. Journal of the National Cancer Institute, 2020, 112, 295-304.	6.3	35
29	Novel functional proteins coded by the human genome discovered in metastases of melanoma patients. Cell Biology and Toxicology, 2020, 36, 261-272.	5.3	9
30	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. International Journal of Cancer, 2020, 146, 2130-2138.	5.1	13
31	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
32	Tumor genetic heterogeneity analysis of chronic sunâ€damaged melanoma. Pigment Cell and Melanoma Research, 2020, 33, 480-489.	3.3	22
33	Increased Cancer Risk in Families with Pediatric Cancer Is Associated with Gender, Age, Diagnosis, and Degree of Relation to the Child. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2171-2179.	2.5	2
34	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
35	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
36	Desloratadine and loratadine stand out among common H₁-antihistamines for association with improved breast cancer survival. Acta OncolÃ³gica, 2020, 59, 1103-1109.	1.8	20

#	Article	IF	Citations
37	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
38	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Molecular Oncology, 2020, 14, 933-950.	4.6	29
39	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767.	3.7	2
40	Desloratadine and loratadine use associated with improved melanoma survival. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2096-2099.	5.7	17
41	Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden. Public Health Genomics, 2020, 23, 100-109.	1.0	1
42	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
43	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	27.8	1,209
44	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24
45	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
46	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	5.0	41
47	Women with a predisposition for diabetes have an increased risk of pregnancy complications, especially in combination with pregestational overweight. BMC Pregnancy and Childbirth, 2020, 20, 74.	2.4	5
48	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers, 2020, 12, 742.	3.7	38
49	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
50	Women with fair phenotypes seem to confer a survival advantage in a low UV milieu. A nested matched case control study. PLoS ONE, 2020, 15, e0228582.	2.5	7
51	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
52	Risk factors for subarachnoid haemorrhage: a nationwide cohort of 950Â000 adults. International Journal of Epidemiology, 2019, 48, 2018-2025.	1.9	21
53	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. Molecular and Cellular Proteomics, 2019, 18, 1836-1850.	3.8	42
54	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. Journal of the American Academy of Dermatology, 2019, 81, 386-394.	1.2	17

#	Article	IF	Citations
55	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
56	A single exercise session improves side-effects of chemotherapy in women with breast cancer: an observational study. BMC Cancer, 2019, 19, 1073.	2.6	15
57	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
58	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
59	Rationale for a Swedish cohort consortium. Upsala Journal of Medical Sciences, 2019, 124, 21-28.	0.9	3
60	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Reports, 2019, 27, 3573-3586.e7.	6.4	66
61	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
62	Physical activity and survival following breast cancer. European Journal of Cancer Care, 2019, 28, e13037.	1.5	15
63	Clinical protein science in translational medicine targeting malignant melanoma. Cell Biology and Toxicology, 2019, 35, 293-332.	5.3	33
64	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. Scientific Reports, 2019, 9, 5154.	3.3	12
65	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
66	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600.	5.7	16
67	Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Melanoma Research, 2019, 29, 483-490.	1.2	13
68	The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanomaâ€"Association with Clinical Outcome and Tumor Phenotypes. Cancers, 2019, 11, 1981.	3.7	16
69	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
70	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
71	CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe. Journal of Medical Genetics, 2018, 55, 661-668.	3.2	13
72	Current smoking is associated with a larger waist circumference and a more androgenic profile in young healthy women from high-risk breast cancer families. Cancer Causes and Control, 2018, 29, 243-251.	1.8	7

#	Article	IF	Citations
73	Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer â€“ an observational study. BMC Cancer, 2018, 18, 230.	2.6	4
74	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
75	Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men. European Journal of Nutrition, 2018, 57, 2595-2606.	3.9	11
76	Lung cancer in young women in southern Sweden: A descriptive study. Clinical Respiratory Journal, 2018, 12, 1565-1571.	1.6	12
77	Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer. Acta OncolÃ³gica, 2018, 57, 595-603.	1.8	19
78	Phenocopies in melanoma-prone families with germ-line CDKN2A mutations. Genetics in Medicine, 2018, 20, 1087-1090.	2.4	11
79	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	2.9	21
80	Endogenous expression mapping of malignant melanoma by mass spectrometry imaging. Clinical and Translational Medicine, 2018, 7, 22.	4.0	9
81	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
82	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
83	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
84	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
85	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
86	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
87	<scp>NF</scp>1â€mutated melanoma tumors harbor distinct clinical and biological characteristics. Molecular Oncology, 2017, 11, 438-451.	4.6	112
88	Occupational sedentariness and breast cancer risk. Acta OncolÃ³gica, 2017, 56, 75-80.	1.8	21
89	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
90	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289

#	Article	IF	Citations
91	Germline Variation at CDKN2A and Associations with Nevus Phenotypes amongÂMembers of Melanoma Families. Journal of Investigative Dermatology, 2017, 137, 2606-2612.	0.7	18
92	Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. Journal of the American Academy of Dermatology, 2017, 77, 893-901.	1.2	29
93	Predominance of girls with cancer in families with multiple childhood cancer cases. BMC Cancer, 2017, 17, 868.	2.6	5
94	Impact of Pregestational Weight and Weight Gain during Pregnancy on Long-Term Risk for Diseases. PLoS ONE, 2017, 12, e0168543.	2.5	39
95	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	2.5	27
96	The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer. Breast Cancer: Targets and Therapy, 2016, 8, 117.	1.8	1
97	High <scp>TERT</scp> promoter mutation frequency in nonâ€acral cutaneous metastatic melanoma. Pigment Cell and Melanoma Research, 2016, 29, 598-600.	3.3	22
98	The BRCA1-Î”11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.9	208
99	Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Human Genetics, 2016, 135, 1241-1249.	3.8	24
100	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
101	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. Cancer Research, 2016, 76, 4765-4774.	0.9	86
102	GermlineCDKN2AMutation Status and Survival in Familial Melanoma Cases. Journal of the National Cancer Institute, 2016, 108, djw135.	6.3	47
103	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members ofÂMelanoma Families. Journal of Investigative Dermatology, 2016, 136, 1066-1069.	0.7	13
104	<scp>CDKN2a</scp> mutationâ€negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. International Journal of Cancer, 2015, 137, 2220-2226.	5.1	19
105	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. PLoS ONE, 2015, 10, e0123661.	2.5	19
106	Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Caseâ€“Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 817-824.	2.5	25
107	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	7.0	138
108	The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell and Melanoma Research, 2015, 28, 94-104.	3.3	26

#	Article	IF	Citations
109	Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	134
110	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	21.4	218
111	Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. International Journal of Cancer, 2015, 136, 1351-1360.	5.1	30
112	Tobacco and Alcohol in Relation to Male Breast Cancer: An Analysis of the Male Breast Cancer Pooling Project Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 520-531.	2.5	19
113	Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort. Genes Chromosomes and Cancer, 2015, 54, 39-50.	2.8	6
114	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	1.8	148
115	Epithelial and Stromal MicroRNA Signatures of Columnar Cell Hyperplasia Linking Let-7c to Precancerous and Cancerous Breast Cancer Cell Proliferation. PLoS ONE, 2014, 9, e105099.	2.5	21
116	Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study. Journal of Investigative Dermatology, 2014, 134, 287-290.	0.7	18
117	High risk of tobacco-related cancers inCDKN2Amutation-positive melanoma families. Journal of Medical Genetics, 2014, 51, 545-552.	3.2	73
118	Inherited variation in the PARP1 gene and survival from melanoma. International Journal of Cancer, 2014, 135, 1625-1633.	5.1	24
119	Molecular and genetic diversity in the metastatic process of melanoma. Journal of Pathology, 2014, 233, 39-50.	4.5	58
120	An inherited variant in the gene coding for vitamin <scp>D</scp>â€binding protein and survival from cutaneous melanoma: a <scp>B</scp>io<scp>G</scp>eno<scp>MEL</scp> study. Pigment Cell and Melanoma Research, 2014, 27, 234-243.	3.3	25
121	Plasma Alkylresorcinol Metabolites as Biomarkers for Whole-Grain Intake and Their Association with Prostate Cancer: A Swedish Nested Caseâ€“Control Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 73-83.	2.5	20
122	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 2014, 106, .	6.3	109
123	Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results. Journal of the National Cancer Institute, 2014, 106, djt465-djt465.	6.3	131
124	Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. Journal of Proteome Research, 2014, 13, 1315-1326.	3.7	9
125	High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2014, 147, 571-578.	2.5	47
126	A new look at drugs targeting malignant melanomaâ€”An application for mass spectrometry imaging. Proteomics, 2014, 14, 1963-1970.	2.2	28

#	Article	IF	Citations
127	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. Journal of Investigative Dermatology, 2014, 134, 3000-3003.	0.7	8
128	Oral contraceptive use, parity, and constitutional characteristics in soft tissue sarcoma: a Swedish population-based caseâ€“control study 1988â€“2009. Cancer Causes and Control, 2014, 25, 1167-1177.	1.8	2
129	Investigation of a putative melanoma susceptibility locus at chromosome 3q29. Cancer Genetics, 2014, 207, 70-74.	0.4	3
130	Analysis of Alpha-Synuclein in Malignant Melanoma â€“ Development of a SRM Quantification Assay. PLoS ONE, 2014, 9, e110804.	2.5	20
131	Women Who Develop Diabetes Later in Life Have Diabetes-Associated Complications during Preceding Pregnancies. Journal of Diabetes Mellitus, 2014, 04, 341-349.	0.3	1
132	Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender. Clinical Respiratory Journal, 2013, 7, 91-100.	1.6	10
133	Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clinical and Translational Medicine, 2013, 2, 7.	4.0	15
134	Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	1.6	148
135	Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. SpringerPlus, 2013, 2, 357.	1.2	4
136	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	21.4	111
137	Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules. BMC Clinical Pathology, 2013, 13, 28.	1.8	13
138	Abstract A127: Parental influence on breast cancer penetrance inBRCA1/2mutation carriers: Impact of oral contraceptive use before age 20 years. , 2013, , .		0
139	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
140	The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer. Cancer Research, 2012, 72, 4028-4036.	0.9	41
141	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	7.0	96
142	Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.	7.4	546
143	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nature Genetics, 2012, 44, 1182-1184.	21.4	99
144	Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes and Control, 2012, 23, 769-777.	1.8	49

#	Article	IF	Citations
145	Metal-on-metal joint bearings and hematopoetic malignancy. Monthly Notices of the Royal Astronomical Society: Letters, 2012, 83, 553-558.	3.3	23
146	Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1366-1372.	2.4	24
147	Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. European Journal of Cancer, 2012, 48, 3052-3062.	2.8	17
148	Prevalence of germline TP53 mutations and history of Liâ€“Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: A populationâ€based survey. Pediatric Blood and Cancer, 2012, 59, 846-853.	1.5	17
149	A prospective, populationâ€based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. International Journal of Cancer, 2012, 131, 706-715.	5.1	56
150	Sickness absence among cancer patients in the pre-diagnostic and the post-diagnostic phases of five common forms of cancer. Supportive Care in Cancer, 2012, 20, 741-747.	2.2	41
151	Distribution of aldehyde dehydrogenase 1â€positive stem cells in benign mammary tissue from women with and without breast cancer. Histopathology, 2012, 60, 617-633.	2.9	13
152	Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Research, 2012, 14, R31.	5.0	100
153	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
154	Breast cancer and spider telangiectasias at diagnosis and its relation to histopathology and prognosis: a population-based study. Breast Cancer Research and Treatment, 2012, 131, 177-186.	2.5	1
155	Increased incidence of childhood, prostate and breast cancers in relatives of childhood cancer patients. Familial Cancer, 2012, 11, 145-155.	1.9	7
156	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	21.4	230
157	Increased cancer risks among arthroplasty patients: 30year follow-up of the Swedish Knee Arthroplasty Register. European Journal of Cancer, 2011, 47, 1061-1071.	2.8	52
158	Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families. Molecular Genetics and Metabolism, 2011, 102, 82-90.	1.1	5
159	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, 94-98.	27.8	466
160	Galectin-1-Binding Glycoforms of Haptoglobin with Altered Intracellular Trafficking, and Increase in Metastatic Breast Cancer Patients. PLoS ONE, 2011, 6, e26560.	2.5	41
161	IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer. Familial Cancer, 2011, 10, 173-185.	1.9	15
162	High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Research and Treatment, 2011, 129, 747-760.	2.5	70

#	Article	IF	Citations
163	IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families. Breast Cancer Research and Treatment, 2011, 127, 785-794.	2.5	12
164	Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer. BMC Cancer, 2011, 11, 497.	2.6	6
165	Food Sources of Fat and Sex Hormone Receptor Status of Invasive Breast Tumors in Women of the MalmÃ¶ Diet and Cancer Cohort. Nutrition and Cancer, 2011, 63, 722-733.	2.0	14
166	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
167	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40
168	Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14252-14257.	7.1	68
169	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 2011, 43, 1114-1118.	21.4	140
170	Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype. Melanoma Research, 2010, 20, 266-272.	1.2	8
171	Can a phenotype for recessive inheritance in breast cancer be defined?. Familial Cancer, 2010, 9, 525-530.	1.9	4
172	Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes and Cancer, 2010, 49, 78-90.	2.8	26
173	Analysis of protein expression in pure cell nuclei populations isolated from human breast cancer tissue by DNA flow cytometric sorting. Journal of Proteomics, 2010, 73, 1111-1116.	2.4	3
174	Problems in assessing multiple cutaneous melanoma. A review on the accuracy of a population based cancer registry. Cancer Epidemiology, 2010, 34, 262-266.	1.9	2
175	Plasma Folate Concentrations Are Positively Associated with Risk of Estrogen Receptor Î² Negative Breast Cancer in a Swedish Nested Case Control Study. Journal of Nutrition, 2010, 140, 1661-1668.	2.9	35
176	Low Cancer Rates among Patients with Dementia in a Population-Based Register Study in Sweden. Dementia and Geriatric Cognitive Disorders, 2010, 30, 39-42.	1.5	35
177	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	2.5	37
178	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	5.0	25
179	Are active sun exposure habits related to lowering risk of type 2 diabetes mellitus in women, a prospective cohort study?. Diabetes Research and Clinical Practice, 2010, 90, 109-114.	2.8	53
180	Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Research, 2010, 12, R36.	5.0	251

#	Article	IF	Citations
181	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research, 2010, 12, R42.	5.0	167
182	Sick leave of spouses to cancer patients before and after diagnosis. Acta OncolÃ³gica, 2010, 49, 467-473.	1.8	16
183	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-391.	1.2	30
184	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-91.	1.2	22
185	Increased breast cancer risk at high plasma folate concentrations among women with the MT HFR 677T allele. American Journal of Clinical Nutrition, 2009, 90, 1380-1389.	4.7	43
186	Influence on the Health of the Partner Affected by Tumor Disease in the Wife or Husband Based on a Population-Based Register Study of Cancer in Sweden. Journal of Clinical Oncology, 2009, 27, 4781-4786.	1.6	58
187	Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. International Journal of Epidemiology, 2009, 38, 814-830.	1.9	219
188	The Protective Association of High Plasma Enterolactone with Breast Cancer Is Reasonably Robust in Women with Polymorphisms in the Estrogen Receptor Î± and Î² Genes. Journal of Nutrition, 2009, 139, 993-1001.	2.9	34
189	Folate Intake, Methylenetetrahydrofolate Reductase Polymorphisms, and Breast Cancer Risk in Women from the Malmoˆ Diet and Cancer Cohort. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1101-1110.	2.5	59
190	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610.	2.5	130
191	Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer, 2009, 9, 140.	2.6	43
192	Proliferative activity and number of clonal chromosome aberrations in non-Hodgkin's lymphomas. Scandinavian Journal of Haematology, 2009, 37, 106-110.	0.0	3
193	A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. International Journal of Cancer, 2009, 124, 420-428.	5.1	84
194	A populationâ€based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. International Journal of Cancer, 2009, 125, 421-425.	5.1	9
195	The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. British Journal of Haematology, 2009, 144, 234-240.	2.5	75
196	Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 2009, 41, 920-925.	21.4	422
197	Expression of Helix pomatia Lectin Binding Glycoproteins in Women with Breast Cancer in Relationship to Their Blood Group Phenotypes. Journal of Proteome Research, 2009, 8, 782-786.	3.7	11
198	Selection criteria for genetic assessment of patients with familial melanoma. Journal of the American Academy of Dermatology, 2009, 61, 677.e1-677.e14.	1.2	154

#	Article	IF	Citations
199	Increased mortality in prostate carcinoma and smoking-related disease after parietal cell vagotomy: A long-term follow-up study. Scandinavian Journal of Gastroenterology, 2009, 44, 947-951.	1.5	11
200	Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk. Familial Cancer, 2008, 7, 221-228.	1.9	11
201	Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Familial Cancer, 2008, 7, 331-337.	1.9	32
202	Do both heterocyclic amines and omegaâ€6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the MalmÃ¶ diet and cancer cohort?. International Journal of Cancer, 2008, 123, 1637-1643.	5.1	29
203	Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 2008, 40, 838-840.	21.4	209
204	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics, 2008, 40, 102-107.	21.4	316
205	The prognostic implication of cytogenetic findings in non-Hodgkin lymphomas. Clinical Genetics, 2008, 29, 464-464.	2.0	0
206	C-band polymorphism in non-Hodgkin lymphoma. Hereditas, 2008, 103, 85-87.	1.4	5
207	Breakprone chromosome bands in fibroblasts from patients with non-Hodgkin's lymphoma do not coincide with bands involved in primary rearrangements in non-Hodgkin's lymphomas. Hereditas, 2008, 109, 131-137.	1.4	4
208	Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. European Journal of Cancer, 2008, 44, 472-480.	2.8	106
209	Enterolactone Is Differently Associated with Estrogen Receptor Î²â€“Negative and â€“Positive Breast Cancer in a Swedish Nested Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3241-3251.	2.5	28
210	Plant foods and oestrogen receptor Â- and Â-defined breast cancer: observations from the Malmo Diet and Cancer cohort. Carcinogenesis, 2008, 29, 2203-2209.	2.8	45
211	Time to Diagnosis of Melanoma: Same Trend in Different Continents. Journal of Cutaneous Medicine and Surgery, 2007, 11, 137-144.	1.2	18
212	Regression analysis and modelling of data acquisition for SELDI-TOF mass spectrometry. Bioinformatics, 2007, 23, 1401-1409.	4.1	11
213	Oral Contraceptives and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study: A Report From EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of Clinical Oncology, 2007, 25, 3831-3836.	1.6	137
214	High folate intake is associated with lower breast cancer incidence in postmenopausal women in the MalmÃ¶ Diet and Cancer cohort. American Journal of Clinical Nutrition, 2007, 86, 434-443.	4.7	99
215	Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle. European Journal of Gastroenterology and Hepatology, 2007, 19, 623-630.	1.6	43
216	Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma. Cancer Letters, 2007, 258, 38-44.	7.2	24

#	Article	IF	Citations
217	In-Source Decay Causes Artifacts in SELDI-TOF MS Spectra. Journal of Proteome Research, 2007, 6, 1609-1614.	3.7	17
218	Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. Familial Cancer, 2007, 6, 445-452.	1.9	6
219	A prospective study on dietary fat and incidence of prostate cancer (MalmÃ¶, Sweden). Cancer Causes and Control, 2007, 18, 1107-1121.	1.8	68
220	Occupational exposure to endocrine-disrupting compounds and biliary tract cancer among men. Scandinavian Journal of Work, Environment and Health, 2007, 33, 387-396.	3.4	14
221	Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families. European Journal of Cancer Prevention, 2006, 15, 233-241.	1.3	7
222	Occupational factors and risk of adult bone sarcomas: A multicentric case-control study in Europe. International Journal of Cancer, 2006, 118, 721-727.	5.1	26
223	Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284.	5.1	246
224	Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. International Journal of Cancer, 2006, 119, 1052-1060.	5.1	59
225	Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization. Cancer Research, 2005, 65, 7612-7621.	0.9	147
226	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer, 2005, 117, 988-991.	5.1	152
227	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes and Control, 2005, 16, 667-674.	1.8	71
228	Fat From Different Foods Show Diverging Relations With Breast Cancer Risk in Postmenopausal Women. Nutrition and Cancer, 2005, 53, 135-143.	2.0	17
229	Mapping of a Novel Ocular and Cutaneous Malignant Melanoma Susceptibility Locus to Chromosome 9q21.32. Journal of the National Cancer Institute, 2005, 97, 1377-1382.	6.3	63
230	Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. European Journal of Cancer, 2005, 41, 2312-2320.	2.8	57
231	High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer risk. Molecular Genetics and Metabolism, 2005, 86, 320-327.	1.1	9
232	Occupational Exposures and Non-Hodgkin's Lymphoma in Southern Sweden. International Journal of Occupational and Environmental Health, 2004, 10, 13-21.	1.2	61
233	The need for oncogenetic counselling Ten yearsâ€™ experience of a regional oncogenetic clinic. Acta OncolÃ³gica, 2004, 43, 637-649.	1.8	11
234	Alcohol Drinking May Increase Risk of Breast Cancer in Men: A European Population-Based Caseâ€“Control Study. Cancer Causes and Control, 2004, 15, 571-580.	1.8	66

#	Article	IF	Citations
235	High fat and alcohol intakes are risk factors of postmenopausal breast cancer: A prospective study from the MalmÃ¶ diet and cancer cohort. International Journal of Cancer, 2004, 110, 589-597.	5.1	29
236	Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables. Anticancer Research, 2004, 24, 2681-7.	1.1	13
237	Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer, 2003, 97, 1387-1392.	4.1	145
238	Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier. Laboratory Investigation, 2003, 83, 387-396.	3.7	43
239	Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2mutation status. Breast Cancer Research, 2003, 5, R175-86.	5.0	37
240	Molecular classification of familial non- BRCA1/BRCA2 breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2532-2537.	7.1	182
241	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	6.3	318
242	Genetic testing for melanoma. Lancet Oncology, The, 2002, 3, 653-654.	10.7	106
243	Postmenopausal breast cancer is associated with high intakes of omega6 fatty acids (Sweden). Cancer Causes and Control, 2002, 13, 883-893.	1.8	76
244	High frequency of microsatellite instability and loss of mismatchâ€repair protein expression in patients with double primary tumors of the endometrium and colorectum. Cancer, 2002, 94, 2502-2510.	4.1	1
245	Gene-Expression Profiles in Hereditary Breast Cancer. New England Journal of Medicine, 2001, 344, 539-548.	27.0	1,669
246	Haplotype analysis and age estimation of the 113insRCDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes and Cancer, 2001, 31, 107-116.	2.8	39
247	Increased cancer risk in offspring of women with colorectal carcinoma. Cancer, 2000, 89, 741-749.	4.1	15
248	Sunscreen use and malignant melanoma. International Journal of Cancer, 2000, 87, 145-150.	5.1	119
249	Somatic frameshift alterations in mononucleotide repeatâ€containing genes in different tumor types from an HNPCC family with germline MSH2 mutation. Genes Chromosomes and Cancer, 2000, 29, 33-39.	2.8	30
250	Estrogen receptor content in malignant breast tumors in men--a review. , 2000, 5, 283-287.		17
251	Familial Breast and Ovarian Cancer: A Swedish Population-based Register Study. American Journal of Epidemiology, 2000, 152, 1154-1163.	3.4	66
252	Increased cancer risk in offspring of women with colorectal carcinoma. Cancer, 2000, 89, 741-749.	4.1	1

#	Article	IF	Citations
253	Reproductive factors in hereditary breast cancer. Breast Cancer Research and Treatment, 1999, 58, 293-299.	2.5	16
254	Somatic genetic alterations inBRCA2-associated and sporadic male breast cancer. Genes Chromosomes and Cancer, 1999, 24, 56-61.	2.8	50
255	hMLH1, hMSH2 andhMSH6 mutations in hereditary non-polyposis colorectal cancer families from Southern Sweden. , 1999, 83, 197-202.		26
256	Correlation between p53, c-erbB-2, and topoisomerase II? expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. , 1999, 187, 207-216.		103
257	A review of the epidemiology of soft tissue sarcoma. Acta Orthopaedica, 1999, 70, 8-10.	1.4	9
258	Correlation between p53, câ€erbBâ€2, and topoisomerase IIÎ± expression, DNA ploidy, hormonal receptor status and proliferation in 356 nodeâ€negative breast carcinomas: prognostic implications. Journal of Pathology, 1999, 187, 207-216.	4.5	2
259	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 1998, 83, 310-319.	4.1	170
260	Analysis of Swedish male breast cancer family data: A simple way to incorporate a common sibling effect. , 1998, 15, 201-212.		5
261	Blood Transfusion at Delivery and Risk of Subsequent Malignant Lymphoma in the Mother. Vox Sanguinis, 1998, 75, 145-148.	1.5	12
262	Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet, The, 1998, 352, 1359-1360.	13.7	111
263	Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. New England Journal of Medicine, 1998, 339, 424-428.	27.0	591
264	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 1998, 83, 310-319.	4.1	2
265	Blood Transfusion at Delivery and Risk of Subsequent Malignant Lymphoma in the Mother. Vox Sanguinis, 1998, 75, 145-148.	1.5	2
266	Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Cancer, 1997, 79, 275-283.	4.1	35
267	Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Cancer, 1997, 79, 275-283.	4.1	5
268	Genetic Predisposition to Breast Cancer. Acta OncolÃ³gica, 1996, 35, 1-8.	1.8	20
269	Correlation between karyotypic pattern and clinicopathologic features in 125 breast cancer cases. , 1996, 66, 191-196.		51
270	Overall cancer incidence not increased after prosthetic knee replacement: 14,551 patients followed for 66,622 person-years. , 1996, 68, 30-33.		30

#	Article	IF	Citations
271	Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families. , 1996, 16, 185-188.		25
272	Reproducibility of a Self-Administered Questionnaire for Assessment of Melanoma Risk. International Journal of Epidemiology, 1996, 25, 245-251.	1.9	63
273	Evaluation of in vitro properties of films of saliva substitutes in contact with different surfaces A comparative study with instruments for measurements of friction and rheologic properties. Acta Odontologica Scandinavica, 1995, 53, 334-338.	1.6	4
274	Cutaneous malignant melanoma in South Sweden 1965, 1975, and 1985. A histopathologic review. Cancer, 1994, 73, 1625-1630.	4.1	22
275	Use of Sunbeds or Sunlamps and Malignant Melanoma in Southern Sweden. American Journal of Epidemiology, 1994, 140, 691-699.	3.4	177
276	Flow Cytometric DNA Index and S-Phase Fraction in Breast Cancer in Relation to Other Prognostic Variables and to Clinical Outcome. Acta OncolÃ³gica, 1992, 31, 157-165.	1.8	53
277	Anxiety and Depression in Breast Cancer Patients at Start of Adjuvant Radiotherapy: Relations to age and type of surgery. Acta OncolÃ³gica, 1992, 31, 641-643.	1.8	78
278	Neuroendocrine differentiation in male breast carcinomas. Apmis, 1992, 100, 720-726.	2.0	3
279	One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications?. Cytometry, 1992, 13, 241-249.	1.8	29
280	Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-Phase fraction by flow cytometry. Cytometry, 1992, 13, 577-585.	1.8	51
281	Chromosome I alterations in breast cancer: Allelic loss on Ip and Iq Is related to lymphogenic metastases and poor prognosis. Genes Chromosomes and Cancer, 1992, 5, 311-320.	2.8	80
282	c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. International Journal of Cancer, 1992, 51, 687-691.	5.1	102
283	Deletion of 14q in nonâ€Hodgkin's lymphoma. European Journal of Haematology, 1990, 44, 261-264.	2.2	5
284	Early Oral Contraceptive Use and Breast Cancer Among Premenopausal Women: Final Report From a Study in Southern Sweden. Journal of the National Cancer Institute, 1989, 81, 1000-1004.	6.3	86
285	Relation between occupational exposure to organic solvents and chromosome aberrations in nonâ€Hodgkin's lymphoma. European Journal of Haematology, 1989, 42, 298-302.	2.2	15
286	Phosphorylation and dephosphorylation of hormone-sensitive lipase Interactions between the regulatory and basal phosphorylation sites. FEBS Letters, 1988, 232, 78-82.	2.8	9
287	Head Trauma and Exposure to Prolactin-Elevating Drugs as Risk Factors for Male Breast Cancer. Journal of the National Cancer Institute, 1988, 80, 679-683.	6.3	67
288	Normal frequency of structural chromosome aberrations in fibroblasts from patients with non-Hodgkin's lymphoma. Hereditas, 1988, 109, 277-280.	1.4	4

#	Article	IF	Citations
289	The regulatory and basal phosphorylation sites of hormone-sensitive lipase are dephosphorylated by protein phosphatase-1, 2A and 2C but not by protein phosphatase-2B. FEBS Journal, 1987, 168, 399-405.	0.2	33
290	Survival following combination chemotherapy in advanced high grade nonâ€Hodgkin's lymphomas: Relation to proliferative activity of the lymphoma cells. European Journal of Haematology, 1987, 38, 437-441.	2.2	5
291	RELATIONSHIP BETWEEN CYTOGENETIC FINDINGS AND HISTOPATHOLOGY IN NONâ€HODGKIN LYMPHOMA. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 1-5.	0.3	3
292	CYTOGENETIC STUDIES IN HODGKIN'S DISEASE. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 289-295.	0.3	13
293	Phosphorylation of the basal site of hormone-sensitive lipase by glycogen synthase kinase-4. FEBS Letters, 1986, 209, 175-180.	2.8	26
294	Cytogenetic studies in non-Hodgkin lymphomas-Results from fineneedle aspiration samples. Hereditas, 1985, 103, 63-76.	1.4	30
295	Hypophyseal tumor and gynecomastia preceding bilateral breast cancer development in a man. Cancer, 1984, 53, 1974-1977.	4.1	24
296	PARTIAL PURIFICATION AND PROPERTIES OF A PROTEIN PHOSPHATASE FROM RAT ADIPOSE TISSUE. Biochemical Society Transactions, 1981, 9, 237P-237P.	3.4	0
297	Correlation between p53, c-erbB-2, and topoisomerase IÎ± expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. , 0, .		1